<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03791398</url>
  </required_header>
  <id_info>
    <org_study_id>BrUOG 379</org_study_id>
    <nct_id>NCT03791398</nct_id>
  </id_info>
  <brief_title>BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC</brief_title>
  <acronym>379</acronym>
  <official_title>BrUOG 379: A Phase Ib/II Single Arm Study of ONC201 Plus Nivolumab in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khaldoun Almhanna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncoceutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm Phase Ib/II, open label, safety, pharmacokinetic, pharmacodynamics and&#xD;
      efficacy study of ONC201 in combination with Opdivo (Nivolumab) in adult patients with&#xD;
      metastatic colorectal cancer, for whom no standard therapy is available. This study will&#xD;
      enroll adult patients with metastatic colorectal cancer who progressed after at least two&#xD;
      lines of therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">June 16, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single arm study of de-escalating arms to determine the MTD and then expand the trial.It is not randomized.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose and/or recommended dose of ONC201 with Nivolumab for phase II</measure>
    <time_frame>Cycle 1 (each cycle is approximately 4 weeks) through pre-dosing cycle 2, approximately 1 month</time_frame>
    <description>Dose limiting toxicities defined per protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>During treatment and for 6 months post treatment, approximately 18 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>ONC201 Level 1 (Starting Dose Level)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>625mg ONC201 Cycle 1 Day -7 dose then once week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONC201 Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg ONC201 Cycle 1 Day -7 dose then once week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONC201 Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>375 mg ONC201 Cycle 1 Day -7 dose then once week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>240mg IV flat dose q 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose level 1 ONC201 625mg</intervention_name>
    <description>ONC201 625mg + Nivolumab 240mg IV flat dose</description>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_label>ONC201 Level 1 (Starting Dose Level)</arm_group_label>
    <other_name>ONC201 + Nivolumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose level 2 ONC201 500mg</intervention_name>
    <description>ONC201 500mg + Nivolumab 240mg IV flat dose</description>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_label>ONC201 Level 2</arm_group_label>
    <other_name>ONC201 + Nivolumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose level 3 ONC201 375mg</intervention_name>
    <description>ONC201 375mg + Nivolumab 240mg IV flat dose</description>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_label>ONC201 Level 3</arm_group_label>
    <other_name>ONC201 + Nivolumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have a histologically/cytologically -confirmed primary colorectal tumor,&#xD;
             with confirmation of being microsatellite stable.&#xD;
&#xD;
          2. Radiographic or clinical evidence of metastatic disease that has progressed after at&#xD;
             least 2 prior regimens. Prior bevacizumab, cetuximab, trifluridine and tipiracil , or&#xD;
             regorafenib is allowed, prior FOLFIRI and FOLFOX treatment is required. (Treatment&#xD;
             with a FOLFIRINOX regimen will count as 2 regimens). Prior treatment does not have to&#xD;
             have been in the metastatic setting.&#xD;
&#xD;
          3. Patients must have measurable disease by RECIST criteria&#xD;
&#xD;
          4. All patients must have a tumor(s) located in an area that that can be biopsied as&#xD;
             confirmed by treating physician&#xD;
&#xD;
          5. All patients must submit representative tissue from their malignancy if it is&#xD;
             confirmed there is enough tissue from prior surgery or most recent biopsy.&#xD;
&#xD;
          6. All previous therapies for cancer, including radiotherapy, major surgery and&#xD;
             investigational therapies must be discontinued for ≥ 14 days before the first dose of&#xD;
             ONC201&#xD;
&#xD;
          7. All clinically significant adverse events related to any prior therapy must have&#xD;
             resolved to Grade ≤ 1 Common Terminology Criteria for Adverse Events (CTCAE v5.0),&#xD;
             except alopecia or parameters defined in this eligibility list.&#xD;
&#xD;
          8. Age ≥ 18 years.&#xD;
&#xD;
          9. ECOG performance status ≤ 2.&#xD;
&#xD;
         10. Adequate organ and marrow function as defined below:&#xD;
&#xD;
               1. Absolute neutrophil count ≥1,000/mm3 without growth factor use ≤ 7 days prior to&#xD;
                  treatment&#xD;
&#xD;
               2. Platelets ≥75,000/mm3 without platelet transfusion ≤ 7 days prior to treatment&#xD;
&#xD;
               3. Hemoglobin&gt;8.0 mg/dL without red blood cell transfusion ≤ 7 days prior to&#xD;
                  treatment&#xD;
&#xD;
               4. Total serum bilirubin&lt;1.5 X upper limit of normal (ULN)&#xD;
&#xD;
               5. AST (SGOT)/ALT (SGPT)≤2 X ULN; ≤ 5 X ULN if liver dysfunction is felt to be&#xD;
                  secondary to tumor burden within 14 days prior to treatment, Serum creatinine ≤&#xD;
                  1.5 X ULN (OR creatinine clearance ≥ 60 mL/min/1.73 m2) within 14 days prior to&#xD;
                  treatment&#xD;
&#xD;
               6. Serum or urine pregnancy test (for females of childbearing potential) negative ≤7&#xD;
                  days of treatment&#xD;
&#xD;
         11. Ability to understand and the willingness to sign a written informed consent document&#xD;
             and comply with the study scheduled visits, treatment plans, laboratory tests and&#xD;
             other procedures.&#xD;
&#xD;
         12. Female patients of child-bearing potential must be practicing an effective form of&#xD;
             contraception from the time of informed consent and for the duration of the study&#xD;
             treatment through 5 months after the last dose of drug (ONC201 or Nivolumab, whichever&#xD;
             is administered last). The decision of effective contraception will be based on the&#xD;
             judgment of the principal investigator or a designated associate.&#xD;
&#xD;
         13. Male patients must be surgically sterile (provide date of surgery) or must agree to&#xD;
             use effective contraception from the time of informed consent and for the duration of&#xD;
             the study treatment through 7 months after the last dose of drug (ONC201 or Nivolumab,&#xD;
             whichever is administered last). The decision of effective contraception will be based&#xD;
             on the judgment of the principal investigator or a designated associate.&#xD;
&#xD;
         14. Patients must agree to the required tumor biopsies to enroll in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with symptomatic brain metastases are excluded. Patients with asymptomatic&#xD;
             and treated CNS metastases may participate in this trial. The patient must have&#xD;
             completed any prior treatment for CNS metastases &gt; 28 days prior to registration,&#xD;
             including radiotherapy or surgery. Steroids for the treatment of brain metastasis are&#xD;
             not permitted.&#xD;
&#xD;
          2. Patients with prior treatment with ONC201 will be excluded&#xD;
&#xD;
          3. Active inflammatory gastrointestinal disease such as severe chronic diarrhea (unless&#xD;
             related to underlying malignancy), gastrointestinal perforation, or intra-abdominal&#xD;
             abscess within 6 months prior to study registration. Gastroesophageal reflux disease&#xD;
             under controlled treatment with proton pump inhibitors is allowed.&#xD;
&#xD;
          4. Pregnant or breast feeding.&#xD;
&#xD;
          5. Current active treatment in another clinical study (treatment trial) within 14 days of&#xD;
             D-7.&#xD;
&#xD;
          6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection requiring IV antibiotics, hepatitis, active rheumatologic or collagen&#xD;
             vascular disease, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             clinically significant cardiac arrhythmia, or psychiatric illness/social situations&#xD;
             that would limit compliance with study requirements.&#xD;
&#xD;
          7. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome&#xD;
             (AIDS)-related illness. (testing is not required for eligibility).&#xD;
&#xD;
          8. Any of the following in the previous 3 months: myocardial infarction, severe/unstable&#xD;
             angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure,&#xD;
             cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism&#xD;
             as defined by treating physician.&#xD;
&#xD;
          9. Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or study&#xD;
             drug administration, or may interfere with the interpretation of study results, or in&#xD;
             the judgment of the investigator would make the patient inappropriate for entry into&#xD;
             the study.&#xD;
&#xD;
         10. Participants with an active, known or suspected autoimmune disease. Participants with&#xD;
             type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin&#xD;
             disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment,&#xD;
             or conditions not expected to recur in the absence of an external trigger are&#xD;
             permitted to enroll.&#xD;
&#xD;
         11. Participants with a condition requiring systemic treatment with either corticosteroids&#xD;
             (&gt; 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14&#xD;
             days of day 1 of treatment. Inhaled or topical steroids, and adrenal replacement&#xD;
             steroid doses &gt; 10 mg daily prednisone equivalent, are permitted in the absence of&#xD;
             active autoimmune disease&#xD;
&#xD;
         12. Patients with a history of other invasive malignancies, with the exception of&#xD;
             non-melanoma skin cancer are excluded if there is any evidence of other malignancy&#xD;
             being present within the last three years (2 years for invasive breast cancer).&#xD;
             However, patients with a malignancy that is non-likely to require treatment, as per&#xD;
             the treating physician, in the next 2 years, such as a completely resected, early&#xD;
             stage breast cancer, or other malignancies treated with curative intent are eligible.&#xD;
             Patients are also excluded if their previous cancer treatment contraindicates this&#xD;
             protocol therapy.&#xD;
&#xD;
         13. Prior treatment with immunotherapy for any cancer, including immune checkpoint&#xD;
             inhibitors or anti-CTLA4 agents&#xD;
&#xD;
         14. Participants who have received a live / attenuated vaccine within 30 days of first&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lifespan Cancer Institute: The Miriam and Rhode Island Hospitals</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 26, 2018</study_first_submitted>
  <study_first_submitted_qc>December 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2019</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>Khaldoun Almhanna</investigator_full_name>
    <investigator_title>Principal Investigator: Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>colon cancer</keyword>
  <keyword>microsatellite stable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>TIC10 compound</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

